Cognition Therapeutics Q2 net loss narrows to $6.7 mln

Cognition Therapeutics

07/08/2025 21:10

Overview

Cognition Therapeutics reports Q2 net loss of $6.7 mln, slight improvement from 2024

Company surpasses 50% enrollment in Phase 2 Alzheimer's study

Positive results from dry AMD study with 28.6% reduction in lesion growth

Outlook

Company anticipates FDA decision on DLB breakthrough designation in Q3 2025

Cognition sees FDA milestones aiding potential partnerships for zervimesine

Result Drivers

ALZHEIMER'S STUDY - Surpassed 50% enrollment in Phase 2 study of zervimesine in early Alzheimer's disease

DRY AMD RESULTS - Reported 28.6% reduction in geographic atrophy lesion growth in Phase 2 dry AMD study

DLB PROGRAM - Initiated expanded access program for dementia with Lewy bodies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$6.73 mln
Q2 Income From Operations
-$13.98 mln
Q2 Operating Expenses
$13.98 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cognition Therapeutics Inc is $3.50, about 79.7% above its August 6 closing price of $0.71

Press Release: ID:nGNX3fbRl6

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)